Welcome to our dedicated page for Alaunos Therapeutics news (Ticker: TCRT), a resource for investors and traders seeking the latest updates and insights on Alaunos Therapeutics stock.
Alaunos Therapeutics, Inc. (TCRT) is a clinical-stage leader developing TCR-T cell therapies targeting neoantigens in solid tumors. This page provides centralized access to all material updates from this innovator in precision immuno-oncology.
Investors and researchers will find essential announcements including clinical trial progress, regulatory milestones, and scientific collaborations. Our curated feed ensures timely access to verified updates on therapeutic developments and corporate strategy.
Key content areas include updates on TCR-T platform advancements, partnership announcements with research institutions, and financial disclosures. All information is sourced directly from company filings and authorized communications.
Bookmark this page for efficient tracking of Alaunos' pioneering work in targeting RAS-mutant cancers and other genomic drivers. Check regularly for developments in their mission to transform solid tumor treatment through engineered cellular therapies.
Alaunos Therapeutics (TCRT) announced it will disclose its financial results for Q4 and full year 2022 on March 7, 2023, before U.S. market opening. A conference call is scheduled for 8:30 a.m. ET to discuss results and offer corporate updates. The company focuses on T-cell receptor (TCR) cell therapy aimed at solid tumors, with ongoing Phase 1/2 trials targeting six types of cancer. Alaunos utilizes proprietary platforms for TCR development and collaborates with the National Cancer Institute to advance TCR therapy.
Alaunos Therapeutics (TCRT) announces key milestones for 2023, including the addition of two new TCRs, doubling the addressable market for its TCR-T library. The company aims to enhance patient enrollment in its Phase 1/2 trial focusing on solid tumors. Manufacturing processes are being optimized for scalability, with a shift to cryopreserved products expected to reduce processing time. The mbIL-15 program is also advancing towards an IND filing in the latter half of 2023. As of Q4 2022, Alaunos reported cash and equivalents of approximately $39.1 million, projected to fund operations into Q4 2023.
Alaunos Therapeutics, Inc. (TCRT) announced a public offering of approximately 24.23 million shares at a gross proceeds of $15.7 million. The offering is set to close around December 1, 2022, subject to standard conditions. The funds will be used for the development of its product candidates and general corporate purposes. The underwriter, Cantor Fitzgerald & Co., has a 30-day option to purchase additional shares. A registration statement related to the offering has been filed with the SEC.
Alaunos Therapeutics, Inc. (TCRT) has announced an underwritten public offering of its common stock, with a 30-day option for the underwriter to purchase an additional 15% of shares. The proceeds will be used to support product development, working capital, and general corporate purposes. Cantor Fitzgerald & Co. is the sole book-running manager. The offering is contingent upon market conditions and may not proceed as planned. The registration statement for this offering was declared effective on September 7, 2022, with relevant documents available through the SEC.
Alaunos Therapeutics (TCRT) reports promising early data from its TCR-T Library Phase 1/2 trial, showcasing the first objective clinical response using non-viral Sleeping Beauty TCR-T cell therapy in solid tumors at the CICON conference. The company aims to treat more patients while expanding manufacturing capabilities to produce two products simultaneously. Financially, collaboration revenue surged 631% to $2.9 million, while net loss decreased to $8.9 million, improving cash burn by 36%. An IND amendment is expected to enhance speed and flexibility in manufacturing.
Alaunos Therapeutics (TCRT) will announce its financial results for Q3 2022 on November 14, 2022, prior to U.S. market opening. Following this, a conference call will be held at 8:30 a.m. ET to discuss the results and provide a corporate update. The company specializes in oncology-focused cell therapies, utilizing its proprietary Sleeping Beauty gene transfer technology to develop T-cell receptor therapies targeting oncogenic gene mutations like KRAS, TP53, and EGFR.
Alaunos Therapeutics, Inc. (Nasdaq: TCRT) has announced promising data from its human neoantigen T-cell receptor platform (hunTR) at the Society for Immunotherapy of Cancer's annual meeting. The proprietary hunTR platform enables rapid identification of neoantigen-reactive TCRs, enhancing Alaunos' TCR library. The study evaluated ~525,000 TCR+HLA+neoantigen combinations in patients with various cancers, with a median hit rate of 13% per patient. The company plans to expand the application of hunTR for additional mutations, aiming to advance personalized TCR-T therapies.
Alaunos Therapeutics has announced promising early clinical data from its TCR-T Library Phase 1/2 trial for treating solid tumors. The first patient experienced a confirmed partial response with a 51.2% tumor regression at three months post-infusion. The Sleeping Beauty TCR-T cell therapy demonstrated a manageable safety profile, with no dose-limiting toxicities observed. The data will be presented at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference on September 30, 2022. This therapy targets shared tumor-specific hotspot mutations, offering hope for patients with significant unmet medical needs.
HOUSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, announced participation in several investor conferences. Key events include:
- Wells Fargo Healthcare Conference on September 8, 2022, in Boston, MA (1x1 Meetings)
- Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, in New York, NY (1x1 Meetings)
- Cantor Oncology Conference on September 28, 2022, in New York, NY (Panel Presentation and 1x1 Meetings)
Alaunos Therapeutics has reported significant early findings from its TCR-T Library Phase 1/2 trial, marking a first objective clinical response in solid tumors via non-viral TCR-T cell therapy. The initial patient, diagnosed with non-small cell lung cancer and a KRAS mutation, exhibited a confirmed objective partial response. A second patient has completed the 28-day safety window. The results will be further detailed at the CRI-ENCI-AACR CICON conference on September 30, 2022, highlighting the potential of non-viral TCR-T therapies in treating solid tumors.
